Executive recruitment success―built on insight and analytics
Though it’s a big jump from the initial executive search idea to welcoming a brilliant new leader on their first day, Heritage Partners bridges the gap by finding the right talent to empower your company’s strategy and success.
The following stories may help you better imagine the advantages of building an ideal life science team with us:
Venture capital investment in Digital HealthCare has increased exponentially over the past few years. With $1.8 billion invested globally during the first quarter of 2016 the sector is on track for a significant increase over 2015’s $5.8 billion in venture deals. Many investors believe this is just the tip of the iceberg of opportunity to capitalize on this combination of technology and healthcare process innovation.
In 2016 Heritage Partners, in collaboration with RSA Group, became the leading executive search and advisory firm in the Digital HealthCare sector. Together, Heritage Partners and RSA Group have applied their understanding of technology, the life sciences and healthcare with an extensive network of industry talent to produce the most recent Talent Equity report . This report presents the leading Themes for business models in this sector and profiles 20 leading Digital HealthCare companies along with their CEOs and Technology Heads. You may also enjoy a Digital HealthCare Timeline we’ve developed which illustrates the development of this sector since its origins at the beginning of the 1900’s. It is these insights that enable us to ensure our clients such as Patients Like Me, Bioclinica and The Jackson Laboratory for Genomic Medicine have the executive talent they need to continue to grow in this new and challenging field.
Along with having a hand in supporting numerous Nobel Prize winners, The Jackson Laboratory (JAX) performs early discovery mammalian genetics research, serves as a global source for 7,000+ strains of genetically designed mice, and mentors thousands through its extensive scientific educational programs. Based on this foundation, in 2012, the institution revealed its expanded mission “to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health.”
Underscoring the importance of this shift, in 2014, JAX finished building a new research center in Farmington, Connecticut―The Jackson Laboratory for Genomic Medicine. The new facility will eventually house 300 researchers, technicians and support staff. In collaboration with academic and clinical research partners from Connecticut and around the world, JAX intends to “transform medicine by improving care, lowering costs, and increasing life span and health span.”
To ensure success of this new mission, JAX needed to supplement its executive team with top talent in several key areas within a tight timeframe. Based on the contributions of our prior placements, JAX entrusted this critical task to Heritage Partners. This latest executive search initiative further deepened our relationship, which began in 2006, into a dynamic, deep-seated collaboration JAX can depend on to help shape and perfect the course of its future success.
When Bayer AG divested Gamunex and Prolastin in 2005, these lackluster plasma protein therapeutic products (for people suffering from chronic, acute, often life-threatening blood-related conditions) had a big gap in commercial talent and the anemic sales to prove it. Cerberus Capital Management and Ampersand Ventures acquired them, basing their new standalone company in Research Triangle Park, North Carolina, and naming it Talecris Biotherapeutics.
To help spur rapid, profitable growth, Heritage Partners was asked to rebuild Talecris’ core commercial team from scratch. Meeting one-on-one with top life science candidates nationwide, our partners communicated Talecris’ new energy, strategy and vision. They inspired belief that the company had staying power and something special to offer, and created excitement for an opportunity to shape Talecris’ future success.
Heritage Partners recruited eight people for critical, strategic roles in Talecris’ sales and marketing group. These executives revitalized the company’s stature, culture and how its strategy was executed, and had a direct impact on U.S. sales, which jumped from $460 million to $1.2 billion. This astonishing turnaround was a win:win for investors, management and the people who depend on Talecris’ life-saving therapies, while the company’s subsequent 2012 sale to Grifols provided the highly lucrative exit both investors desired.